Suchergebnisse - "Skanjeti, Andrea"

PubPharm (78)

1

Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence : A Prospective, Randomized, Crossover Multicenter Study

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2023

von Olivier, P. | Giraudet, A. | Skanjeti, A. | +5

2

EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA)

enthalten in: European journal of nuclear medicine and molecular imaging | 2021

von Delgado Bolton, R. | Aide, N. | Colletti, P. | +4

3

Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT : 1084 examinations

enthalten in: European journal of nuclear medicine and molecular imaging | 2021

von Chevalme, Y. | Boudali, L. | Gauthé, M. | +7

CommentIn: Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2690-2691. - PMID 33742238

4

EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA)

enthalten in: European journal of nuclear medicine and molecular imaging | 2021

von Delgado Bolton, R. | Aide, N. | Colletti, P. | +4

5

EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA)

enthalten in: European journal of nuclear medicine & molecular imaging | 2021

von Delgado Bolton, R. | Aide, N. | Colletti, P. | +4

6

EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA)

enthalten in: European journal of nuclear medicine and molecular imaging | 2021

von Delgado Bolton, R. | Aide, N. | Colletti, P. | +4

7

Lymphoscintigraphy for Sentinel Node Mapping in Head and Neck Cancer

enthalten in: Seminars in nuclear medicine | 2021

von Skanjeti, A. | Dhomps, A. | Paschetta, C. | +3

8

Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations

enthalten in: European journal of nuclear medicine and molecular imaging | 2021

von Chevalme, Y. | Boudali, L. | Gauthé, M. | +7

9

Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations

enthalten in: European journal of nuclear medicine & molecular imaging | 2021

von Chevalme, Y. | Boudali, L. | Gauthé, M. | +7

10

Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations

enthalten in: European journal of nuclear medicine and molecular imaging | 2021

von Chevalme, Y. | Boudali, L. | Gauthé, M. | +7

1
2
3
4
5
6
7
8
Nächster »
[8]